secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001493152-26-007268
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LIXTE appoints Sidney Braun CEO of Liora; GBP 50K signing bonus, GBP 25K monthly retainer
--------------------------------------------------------------------------------

- Braun becomes CEO of Liora Technologies Europe Ltd., effective Feb 13, 2026.
- Signing bonus of GBP 50,000 plus monthly retainer of GBP 25,000 (both excl. VAT).
- If Liora is sold, Braun gets 20% of net purchase price via Allocation Deed.
- Braun helped create Liora and facilitated LIXTE's acquisition of Liora's assets in Nov 2025.
- He brings 20+ years healthcare experience; previously built Remicade infusion network.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315226007268/0001493152-26-007268-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315226007268/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-007268

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer